Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
Richard Lafayette(Stanford University), Jens Kristensen, Andrew Stone, Jürgen Floege(RWTH Aachen University), Vladimı́r Tesař(Charles University), Hernán Trimarchi(Hospital Británico de Buenos Aires), Hong Zhang(Peking University), Necmi Eren(Kocaeli Üniversitesi), Alexander Paliege(University Hospital Carl Gustav Carus), Heather N. Reich(University of Toronto), Brad H. Rovin(The Ohio State University Wexner Medical Center), Jonathan Barratt(University of Leicester)
Cited by 276Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis